New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 21, 2014
10:11 EDTXNPTXenoPort urges stockholders to vote for all director nominees
XenoPort announced that it has filed a presentation with the U.S. SEC in connection with the company’s upcoming Annual Meeting, which will be held on June 11. Highlights of the presentation include: XenoPort’s Board of Directors and management team are committed to realizing the full potential of XenoPort’s assets; XenoPort’s Board is active and engaged, and has the depth, diversity of skills and expertise needed to oversee the execution of XenoPort’s strategy; XenoPort is making meaningful progress commercializing and building value in HORIZANT Extended-Release Tablets. With its focused commercial efforts involving just ~40 sales reps, XenoPort recently achieved a level of prescribed HORIZANT tablets, based on the four-week period ending May 9, that corresponds to an annualized gross demand sales run-rate of $25M; XenoPort is committed to optimizing the value of XP23829, and is taking appropriate steps to move it through the development process.
News For XNPT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 28, 2015
09:24 EDTXNPTJefferies sees Pharma M&A continuing, lists 22 possible targets
Jefferies analyst David Steinberg believes the M&A wave in the Pharmaceuticals space that began in 2005 can continue as the key drivers remain largely intact. In a note titled "Who is Next? The Feeding Frenzy in Specialty Pharmaceuticals," Steinberg sees deals continuing amid cheap debt, the push for lower corporate taxes and investors rewarding many acquirers for their transactions. He points out there are now around 100 publicly traded Specialty Pharmaceutical companies following the recent life sciences IPO boom. Potential takeover targets, according to Steinberg, include Valeant (VRX), Shire (SHPG), Perrigo (PRGO), Zoetis (ZTS), Mallinckrodt (MNK), Jazz Pharmaceuticals (JAZZ), United Therapeutics (UTHR), Pacira (PCRX), Indivior, Insys Therapeutics (INSY), The Medicines Co. (MDCO), Depomed (DEPO), Spectrum (SPPI), KYTHERA (KYTH), Revance (RVNC), XenoPort (XNPT), Mylan (MYL), Akorn (AKRX), Impax (IPXL), Amphastar Pharmaceuticals (AMPH), Anacor (ANAC) and BioDelivery Sciences (BDSI).

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use